WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...

Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product sales CAMBRIDGE, MA and DURHAM, ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc, a next generation gene-editing company, today announced that it has received an award from the Cystic Fibrosis Foundation to ...

ElevateBio has enjoyed a close look at Life Edit Therapeutics over the past 11 months, with overlaps in the management team and involvement in its portfolio of cell and gene therapy companies giving ...

Novo Nordisk (NVO) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced ...

Moderna Inc. MRNA announced Wednesday a collaboration agreement with privately held Life Edit Therapeutics Inc. to discover and develop in vivo gene editing therapies. Moderna’s stock edged up 0.4% in ...

Novo Nordisk, a health sciences manufacturer, is partnering with Durham’s Life Edit Therapeutics in a deal worth upwards of $1.92 billion. Photo courtesy Novo Nordisk A fast-growing Durham gene ...

DURHAM – Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Life ...

Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially ...